[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338736-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338736-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinical-impact-of-tp53-mutations-in-patients-with-head-and-neck-cancer-who-were-treated-with-targeted-therapies-or-immunotherapy","Clinical Impact of TP53 Mutations in Patients with Head and Neck Cancer Who Were Treated with Targeted Therapies or Immunotherapy","","Tumor suppressor p53 (TP53) mutations are frequent in head and neck squamous cell carcinoma (HNSCC), and their clinical significance in patients receiving precision medicines remains important. Using the KCSG HN15-16 TRIUMPH multicenter umbrella trial in Korea, patients were assigned by genomic profiles to targeted agents or immunotherapy. Across 179 patients, TP53 mutations associated with worse progression-free and overall survival. Results further suggested particularly poor outcomes in the immunotherapy group.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinical-impact-of-tp53-mutations-in-patients-with-head-and-neck-cancer-who-were-treated-with-targeted-therapies-or-immunotherapy/338736/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinical-impact-of-tp53-mutations-in-patients-with-head-and-neck-cancer-who-were-treated-with-targeted-therapies-or-immunotherapy/338736.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were patients grouped in the TRIUMPH trial analysis?","Question",{"text":63,"@type":64},"Patients were allocated based on genomic profiles into groups receiving alpelisib, poziotinib, nintedanib, abemaciclib, and—when no identifiable target existed—durvalumab ± tremelimumab.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the study find about progression-free survival for TP53-mutant patients?",{"text":68,"@type":64},"TP53 mutations showed shorter progression-free survival than TP53 wild-type in all patients and also among those treated with targeted therapies.",{"name":70,"@type":61,"acceptedAnswer":71},"How did TP53 mutations relate to overall survival?",{"text":72,"@type":64},"TP53 mutations were strongly associated with poorer overall survival compared with TP53 wild-type across the overall cohort and specifically in group 5.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338736,1791670328,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","[https://doi.org/10.4143/crt.2024.836](https://doi.org/10.4143/crt.2024.836) Cancer Res Treat. 2025;57(3):709-719  \nOriginal Article  \nClinical Impact of TP53 Mutations in Patients with Head and Neck Cancer Who Were Treated with Targeted Therapies or Immunotherapy  \nEun Joo Kang1 , Shinwon Hwang2 , Yun-Gyoo Lee3 , Jong-Kwon Choi4 , Seong Hoon Shin5 , Yoon Hee Choi6 , Keun-WookLee7 , Hyun WooLee8 , Min Kyoung Kim9 , Seung Taek Lim10 , Hwan Jung Yun11 , Sang-Gon Park12 , Sangwoo Kim13 , Sung-Bae Kim14, HyeRyun Kim15  \n*A list of author’s affiliations appears at the end of the paper.  \nPurpose Tumor suppressor p53 (TP53) mutations are common in head and necksquamous cell carcinoma (HNSCC). We evaluated their clinical impact in patients treated with targeted agents or immunotherapy in the KCSG HN15-16 TRIUMPH trial.  \nMaterials and Methods We analyzed clinical characteristics and outcomes of patients with TP53 mutations in the TRIUMPH trial, amulticenter, biomarker-driven umbrella trial in Korea. Patients were assigned to treatment groups based on genomic profiles: group 1, alpelisib; group 2, poziotinib; group 3, nintedanib; and group 4, abemaciclib. If there was no identifiable target, the patients were allocated to group 5 (durvalumab±tremelimumab).  \nResults TP53 mutations were detected in 116/179 patients (64.8%), more frequently in human papillomavirus–negative and non-oropharyngeal cancers. Patients with TP53 mutations exhibited shorter progression-free survival than TP53 wild-type in all the patients (1.7 vs. 3.8 months, p=0.002) and in those who received targeted treatments (2.5 vs. 7.3 months, p=0.009). Furthermore, TP53 mutations were strongly associated with poor overall survival than TP53 wild-type in all the patients (11.1 vs. 28.8 months, p=0.005) and in group 5 (8.1 vs. 33.0 months, p=0.001).  \nConclusion TP53 mutations were associated with aggressive clinical characteristics and poor survival, particularly in HNSCC patients treated with immunotherapy.  \nKey words Head and neck neoplasms, Tumor suppressor protein P53, Next generation sequencing, Immunotherapy, Molecular targeted therapy  \nIntroduction  \nThe tumor suppressor p53 (TP53) gene, a crucial tumor suppressor gene that has been implicated in various cancers, encodes the p53 protein. This protein controls cell division and death at a low level in normal tissue [1,2] . However, mutations in the TP53 gene due to numerous endogenous or exogenous stressors can cause a loss or gain of function of the wild-type TP53, which promotes the proliferation, invasion, and metastasis of cancer cells. The TP53 mutations are frequently detected in head and neck squamous cell carcinomas (HNSCCs) and are associated with shorter survival times and resistance to chemotherapy or radiotherapy [3] .  \nGenomic sequencing techniques are being increasingly integrated into routine diagnostic processes for precision medicine. Thus, clinicians can now readily identify patients with HNSCC who harbor the TP53 mutations via next-gen-  \neration sequencing (NGS) in a clinical setting. Concurrently, with the advancement of genomic alteration detection and availability of various targeted agents as well as immunooncology drugs, several patients with metastatic and advanced HNSCC can now receive individualized treatments. Therefore, there is a pressing need to thoroughly investigate the clinical significance of TP53 mutations in patients with HNSCC who are being treated with novel drugs in the era of precision medicine.  \nIn South Korea, a large-scale clinical trial, the Translational Biomarker-driven Umbrella Project for Head and Neck Squamous Cell Carcinoma (TRIUMPH), was conducted. In this multicenter, prospective, and umbrella trial, treatment regimens were allocated patients with recurrent and/or metastatic HNSCC on the basis of their individual NGS results. The clinical trial included the use of alpelisib, poziotinib, nintedanib, abemaciclib and durvalumab with or without  \nCorrespondence:","cbCailwaDwgaccWP","https://ap.wps.com/l/cbCailwaDwgaccWP","pdf",1373893,11,"English","# Purpose\n# Materials and Methods\n## Study design\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"How were patients grouped in the TRIUMPH trial analysis?\",\"answer\":\"Patients were allocated based on genomic profiles into groups receiving alpelisib, poziotinib, nintedanib, abemaciclib, and—when no identifiable target existed—durvalumab ± tremelimumab.\"},{\"question\":\"What did the study find about progression-free survival for TP53-mutant patients?\",\"answer\":\"TP53 mutations showed shorter progression-free survival than TP53 wild-type in all patients and also among those treated with targeted therapies.\"},{\"question\":\"How did TP53 mutations relate to overall survival?\",\"answer\":\"TP53 mutations were strongly associated with poorer overall survival compared with TP53 wild-type across the overall cohort and specifically in group 5.\"}]","Clinical Impact of TP53 Mutations in Patients with Head and Neck Cancer Who Were Treated with Targeted Therapies or Immunotherapy | PDF",1790025384,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcbb503957fc82e0121da1a28c865a0a.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/282fb1d991a01682d01a749da1e1fb0d.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3914ba98e1f7b3110f4f1736a2399032.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13bcb2cd4a171c73ffb7e8d669e1baa2.webp",980,1306]